LU86383A1 - Solutions a base de phenytoine,leur procede de preparation et leur application pharmaceutique - Google Patents

Solutions a base de phenytoine,leur procede de preparation et leur application pharmaceutique Download PDF

Info

Publication number
LU86383A1
LU86383A1 LU86383A LU86383A LU86383A1 LU 86383 A1 LU86383 A1 LU 86383A1 LU 86383 A LU86383 A LU 86383A LU 86383 A LU86383 A LU 86383A LU 86383 A1 LU86383 A1 LU 86383A1
Authority
LU
Luxembourg
Prior art keywords
sodium
solution
phenytotne
phenytoin
chollne
Prior art date
Application number
LU86383A
Other languages
English (en)
French (fr)
Inventor
Mahdi B Fawzi
Anne K Taylor
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of LU86383A1 publication Critical patent/LU86383A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LU86383A 1985-05-20 1986-04-01 Solutions a base de phenytoine,leur procede de preparation et leur application pharmaceutique LU86383A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/735,932 US4642316A (en) 1985-05-20 1985-05-20 Parenteral phenytoin preparations
US73593285 1985-05-20

Publications (1)

Publication Number Publication Date
LU86383A1 true LU86383A1 (fr) 1986-09-02

Family

ID=24957819

Family Applications (1)

Application Number Title Priority Date Filing Date
LU86383A LU86383A1 (fr) 1985-05-20 1986-04-01 Solutions a base de phenytoine,leur procede de preparation et leur application pharmaceutique

Country Status (18)

Country Link
US (1) US4642316A (es)
JP (1) JPS61268618A (es)
AU (1) AU595790B2 (es)
BE (1) BE904476A (es)
CA (1) CA1268119A (es)
CH (1) CH668594A5 (es)
DE (1) DE3610330A1 (es)
DK (1) DK100786A (es)
ES (1) ES8707195A1 (es)
FR (1) FR2581871B1 (es)
GB (1) GB2175203B (es)
IT (1) IT1190282B (es)
LU (1) LU86383A1 (es)
NL (1) NL8600899A (es)
NZ (1) NZ215783A (es)
PH (1) PH22922A (es)
SE (1) SE8600998L (es)
ZA (1) ZA862094B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3828156A1 (de) * 1988-08-19 1990-02-22 Astrapin Pharmazeutische Praep Stabile waessrige loesung von fluorouracil
AU8479998A (en) * 1997-07-22 1999-02-16 Warner-Lambert Company Lyophilized fosphenytoin sodium for parenteral use
AU1917899A (en) 1998-03-20 1999-10-18 Warner-Lambert Company Crystalline sodium phenytoin monohydrate
US6274168B1 (en) 1999-02-23 2001-08-14 Mylan Pharmaceuticals Inc. Phenytoin sodium pharmaceutical compositions
AU2003300986A1 (en) * 2002-12-16 2004-07-22 Ashish Madan An extended release pharmaceutical composition of phenytoin sodium
NZ589276A (en) 2005-02-03 2012-06-29 Topotarget Uk Ltd Combination therapies using hdac inhibitors and erlotinib (tarceva)
DE102005019393A1 (de) * 2005-04-25 2006-10-26 Basell Polyolefine Gmbh Polyethylenformmassen für Spritzgussanwendungen
SI1901729T1 (sl) 2005-05-13 2012-05-31 Topotarget Uk Ltd Farmacevtske formulacije HDAC inhibitorjev
AU2012213940B2 (en) * 2005-05-13 2015-03-26 Topotarget Uk Limited Pharmaceutical formulations of HDAC inhibitors
CA2627923C (en) * 2005-11-10 2016-01-12 Topotarget Uk Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer
US8377979B2 (en) * 2005-12-05 2013-02-19 Taro Pharmaceuticals North America, Inc. Pharmaceutical formulation containing phenytoin sodium and magnesium stearate
CN101868446A (zh) * 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
SI2262493T1 (sl) * 2008-03-07 2015-07-31 Onxeo Dk Branch Of Onxeo S.A. France Postopki zdravljenja z uporabo podaljšane kontinuirane infuzije belinostata
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
PT3192500T (pt) 2009-05-19 2021-01-05 Neuroderm Ltd Composições para a administração contínua de inibidores da dopa decarboxilase
DK2640358T3 (en) 2010-11-15 2018-04-16 Neuroderm Ltd CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA-DECARBOXYLASE INHIBITORS, CATECHOL-O-METHYL TRANSFERASE INHIBITORS AND COMPOSITIONS THEREOF
US9540330B2 (en) 2010-12-15 2017-01-10 Nektar Therapeutics Oligomer-containing hydantoin compounds
EP2854764B1 (en) 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
PL3777833T3 (pl) 2014-03-13 2024-03-25 Neuroderm Ltd. Kompozycje inhibitorów dekarboksylazy dopa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
WO2023205615A1 (en) 2022-04-18 2023-10-26 ISHA Therapeutics LLC Orally dissolving antimicrobial film compositions & methods of their use
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3749779A (en) * 1970-08-27 1973-07-31 American Home Prod Stable solutions of sodium diphenylhydantoin
JPS5221575B2 (es) * 1972-03-18 1977-06-11
US4260769A (en) * 1977-04-22 1981-04-07 Interx Research Corporation 5,5-Diphenylhydantoins
US4163058A (en) * 1977-04-22 1979-07-31 Interx Research Corporation Derivatives of 5,5-diphenylhydantoin exhibiting enhanced solubility and the therapeutic use thereof

Also Published As

Publication number Publication date
SE8600998D0 (sv) 1986-03-05
PH22922A (en) 1989-01-24
GB2175203B (en) 1988-09-14
IT8647936A1 (it) 1987-10-24
DK100786A (da) 1986-11-21
DE3610330A1 (de) 1986-11-20
IT1190282B (it) 1988-02-16
US4642316A (en) 1987-02-10
GB2175203A (en) 1986-11-26
DK100786D0 (da) 1986-03-05
ES555143A0 (es) 1987-07-16
NZ215783A (en) 1989-01-27
AU595790B2 (en) 1990-04-12
GB8607383D0 (en) 1986-04-30
FR2581871B1 (fr) 1990-05-11
JPS61268618A (ja) 1986-11-28
FR2581871A1 (fr) 1986-11-21
CH668594A5 (fr) 1989-01-13
AU5441286A (en) 1986-11-27
ZA862094B (en) 1986-11-26
ES8707195A1 (es) 1987-07-16
CA1268119A (en) 1990-04-24
BE904476A (fr) 1986-09-24
IT8647936A0 (it) 1986-04-24
NL8600899A (nl) 1986-12-16
SE8600998L (sv) 1986-11-21

Similar Documents

Publication Publication Date Title
FR2581871A1 (fr) Solutions a base de phenytoine, leur procede de preparation et leur application pharmaceutique
CA2102778C (fr) Nouvelles compositions a base de derives de la classe des taxanes
EP0078785B1 (fr) Sels d'acide valproîque, leur préparation et leur utilisation
US4409233A (en) Highly concentrated preparations of dopa compounds
FR2584405A1 (fr) Sels de furosemide, composition pharmaceutique les contenant et leur procede de preparation
JP5297815B2 (ja) 医薬組成物
EP0835140B1 (fr) Complexes metalliques de polyaminoacides et leur utilisation en imagerie diagnostique
CA1281650C (en) Aqueous preparation containing cyclodextrin
JP5325779B2 (ja) 医薬組成物
EP0099799B1 (fr) Nouveaux sels d'amino- (et imino-) acides alpha, omega-sulfoniques N-substitués, vecteurs cationiques de haute pénétration cellulaire, procédé d'obtention
EP0244315A1 (fr) Procédé de préparation d'une solution pharmaceutique aqueuse d'un principe actif constitué par un acide organique
JP3917820B2 (ja) オザグレルナトリウム含有注射液およびその安定化方法
RU2313346C2 (ru) Фармацевтическая композиция
EP0092287B2 (fr) Sels d'acétylcystéine, leur préparation et leur utilisation
EP0920320A2 (fr) Composition pharmaceutique injectable contenant l'acide ursodesoxycholique ou l'acide tauroursodesoxycholique, une base forte et du trometamol
FR2690340A1 (fr) Nouveau procédé de stabilisation des préparations pharmaceutiques liquides et les compositions pharmaceutiques ainsi stabilisées en résultant.
RU2389491C2 (ru) Комплекс, содержащий меквитазин (mequitazine), циклодекстрин и агент взаимодействия
FR2535205A1 (fr) Solution pour injection a base de substances antirhumatismales et d'une cobalamine et procede pour sa preparation
JP2007106736A (ja) 注射用の医薬組成物
JP2003063963A (ja) オザグレルナトリウム含有注射液
JP2007191417A (ja) 医薬用の組成物
LU83081A1 (fr) Compositions antitumeurs
LU84421A1 (fr) Sels d'acide ursodesoxycholique,leur preparation et leur utilisation
BE887220A (fr) Compositions antitumeurs
KR20210073905A (ko) 이부프로펜 및 아르기닌을 함유하는 안정성이 개선된 주사용 제제